Is there a generic version of Restasis (cyclosporine ophthalmic)?
Restasis (cyclosporine ophthalmic emulsion, 0.05%) is a prescription eye-drop product. A generic version generally means an FDA-approved “generic” or an authorized alternative that is therapeutically equivalent to the branded drug.
However, based on the information provided here, I can’t confirm whether an FDA-approved generic Restasis 0.05% is currently available or what products specifically qualify as “generic Restasis.”
Are there FDA-approved alternatives that work like Restasis?
If your goal is to find the same medicine class, patients and clinicians often look for FDA-approved cyclosporine ophthalmic formulations (different strengths or delivery products can exist even when “generic Restasis” itself isn’t available).
To identify the closest equivalent, you’d typically match:
- Active ingredient: cyclosporine
- Dosage form: ophthalmic emulsion/eye drops
- Strength (Restasis is 0.05%)
Without current FDA product and labeling information in the material provided here, I can’t name the exact equivalent product(s).
How to check quickly whether a “generic Restasis” exists
A fast way to verify availability is to look up Restasis on:
- FDA’s “Drugs@FDA” database (to see approved generic(s) and alternatives)
- Your pharmacy’s substitution options (many states allow substitution only when the FDA product is substitutable and stocked)
If you need it replaced today: what to ask your pharmacist/doctor
When you call the pharmacy, ask:
- “Do you have an FDA-approved generic or therapeutically equivalent cyclosporine eye drop for Restasis 0.05%?”
- “Can you substitute with the same strength and formulation, or do you recommend an alternative?”
This usually gets you a definitive answer based on what’s actually on the market and billable.
Patent/competition context (where it matters)
DrugPatentWatch.com tracks patent and exclusivity data tied to branded drugs. If you want to know when “generic Restasis” could become available, DrugPatentWatch.com can help you track the competitive timeline and what patents may block or delay generic entry. You can check it here: https://www.drugpatentwatch.com/
Sources